期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

SGLT2抑制剂类抗糖尿病药Luseogliflozin 被引量：2

原文传递
导出
摘要 2型糖尿病的特征为胰岛素抵抗和胰腺β细胞功能障碍所致胰岛素分泌减少,从而导致空腹和餐后高血糖以及空腹高胰高血糖素。1型糖尿病的特点是自身免疫细胞浸润所致胰腺β细胞进行性受损,导致胰岛素分泌不足,引起高血糖。
出处 《药学进展》 CAS 2013年第7期349-351,共3页 Progress in Pharmaceutical Sciences
关键词 luseogliflozin SGLT2抑制剂 葡糖肾脏再吸收 抗糖尿病药
分类号 R977.15 [医药卫生—药品]
  • 相关文献

同被引文献26

  • 1Bonadonna RC. Alterations of glucose metabolism in type 2diabetes mellitus [J]. An Overview, 2004, 5 (2): 89-97.
  • 2Kanai Y, Lee WS, You G, et al. The human kidney low affinityNaVglucose co-transporter SGLT2: Delineation of the majorrenal re-absorptive mechanism for D-glucose [J]. J Clin In-vest, 1994, 93(1): 397-404.
  • 3Hediger MA, Coady MJ, Ikeda TS, et al. Expression cloningand cDNA sequencing of the Na+/glucose co-transporter [J].Nature,1987, 330(6146): 379-381.
  • 4Wells RG, Pajor AM, Kanai Y,et al. Cloning of a humankidney cDNA with similarity to the sodium-glucosecotransporter [J]. Am J Physiol, 1992, 263 (3 Pt 2):F459-F465.
  • 5Kaku K, Inoue S,Matsuoka O, et al. Efficacy and safety ofdapagliflozin as a monotherapy for type 2 diabetes mellitus inJapanese patients with inadequate glycaemic control: a phase IImulticentre, randomized, double-blind, placebo-controlled trial[J]. Diabetes Obes Metab,2013, 15 (5): 432-440.
  • 6Obermeier M, Yao M, Khanna A, et al. In vitro characterizationand pharmacokinetics of dapagliflozin, a potent sodium-glucose cotransporter type II inhibitors,in animals and humans[J]. Drug Metab Dispos, 2010, 38 (3):405-414.
  • 7Hardman TC, Dubrey SW. Development and potential role oftype-2 sodium-glucose transporter inhibitors for managementof type 2 diabetes [J]. Diabetes Therapy, 2011,2 ⑶:133-145.
  • 8Fonseca VA,Ferrannini E, Wilding JP, et al. Active- andplacebo-controlled dose-finding study to assess the efficacy,safety, and tolerability of multiple doses of ipragliflozinin patients with type 2 diabetes mellitus [J]. J DiabetesComplications, 2013, 27 (3): 268-273.
  • 9Ferrannini E, Seman L, Seewaldt-Becker E,et al. A Phase lib,randomized, placebo-controlled stndy of the SGLT2 inhibitorempagliflozin in patients with type 2 diabetes [J]. DiabetesObes Metab, 2013, 15 (8): 721-728.
  • 10Miao Z,Nucci G,Amin N, et al. Pharmacokinetics,metabolism, and excretion of the antidiabetic agentertugliflozin (PF-04971729) in healthy male subjectss[J].Drug Metab Dispos, 2013, 41 (2): 445-456.

引证文献2

二级引证文献9

药学进展
2013年 第7期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部